PinkDx

Cover Block

PUBLIC

Name	PinkDx
Tagline	Developing non-invasive diagnostic tests for early detection of gynecological cancers using multi-omics and machine learning.
Headquarters	Daly City, California
Founded	2022
Stage	Series A
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	$50M+ (total disclosed ~$45,000,000)

Links

PUBLIC

• Website: https://www.pinkdx.com/
• LinkedIn: https://www.linkedin.com/company/pinkdx

Executive Summary

PUBLIC PinkDx is developing a non-invasive diagnostic platform for the early detection of gynecological cancers, a segment where vague symptoms and invasive procedures have long complicated the diagnostic journey [PinkDx]. The company, founded in 2022, is pursuing a specific wedge: a simple vaginal swab test for endometrial cancer, aiming to provide a more accessible and less traumatic alternative to traditional surgical biopsies [PR Newswire, April 2026]. This approach is backed by peer-reviewed evidence published in April 2026, which the company cites as a key validation milestone for its underlying science. The founding team brings direct, relevant experience from the diagnostics industry. Co-founder Bonnie Anderson previously co-founded and served as CEO of Veracyte, a publicly traded diagnostics company known for its Afirma thyroid cancer test, providing a track record of commercializing novel tests [SPEEDA Edge]. Co-founder Giulia Kennedy served as Chief Scientific Officer at Veracyte, anchoring the venture in deep scientific and product development expertise. To date, PinkDx has raised approximately $45 million across two Series A rounds, with investors including Catalio Capital Management, The Production Board, and the Mayo Clinic [PR Newswire, April 2024] [The Company Check]. While the specific business model is not publicly detailed, the company's focus on a diagnostic test suggests a path toward a lab-developed test (LDT) service or an in-vitro diagnostic (IVD) kit. Over the next 12-18 months, the key watchpoints will be the progression of its endometrial cancer test through clinical validation and regulatory pathways, the announcement of any initial commercial partnerships, and potential expansion into other gynecological cancers. Data Accuracy: GREEN -- Core company details and funding confirmed by multiple public sources including PR Newswire and Crunchbase; founding team background corroborated by independent business profiles.

Taxonomy Snapshot

Axis	Classification
Stage	Series A
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	$50M+ (total disclosed ~$45,000,000)

Company Overview

PUBLIC

PinkDx emerged in 2022 from Daly City, California, with a specific mission to apply modern diagnostic science to women's health [PitchBook]. The company's founding narrative is anchored by a team with a track record in commercializing novel diagnostics, led by co-founder Bonnie Anderson, who previously co-founded and served as CEO of Veracyte, a company known for its Afirma thyroid cancer test [SPEEDA Edge]. This background suggests a deliberate focus on navigating the regulatory and commercial pathways for new clinical tests from the outset.

The company's first major public milestone was its launch in April 2024, backed by a $40 million Series A financing round led by Catalio Capital Management [PR Newswire, April 2024]. This capital injection was explicitly earmarked for developing diagnostics to address unmet needs in women's healthcare. A subsequent funding event in January 2025 added $5 million to the Series A, bringing the total disclosed raise to approximately $45 million [The Company Check]. The investor syndicate includes notable names like Mayo Clinic, The Production Board (TPB), and BVF, signaling institutional validation of the technical approach [PR Newswire, April 2024] [The Company Check].

A key scientific milestone followed in April 2026, when the company announced the publication of peer-reviewed evidence demonstrating that molecular signals for endometrial cancer could be detected from a simple vaginal swab [PR Newswire, April 2026]. This publication represents a critical step in translating the company's core technological premise into validated, publishable science, moving beyond concept toward clinical evidence.

Data Accuracy: YELLOW -- Company founding and funding details are corroborated by multiple databases and press releases. Specific round details and investor roles for the 2025 tranche lack a primary source with a clear date.

Product and Technology

MIXED The company's primary technical effort is a non-invasive diagnostic test for endometrial cancer, a common gynecological malignancy. According to the company's website, PinkDx is "developing a non-invasive vaginal swab test for early detection of endometrial cancer" [PinkDx]. This approach is positioned as a direct alternative to the current diagnostic standard, which often involves invasive and costly procedures like endometrial biopsy or dilation and curettage (D&C). The test aims to address a specific clinical challenge: women presenting with non-specific symptoms such as abnormal uterine bleeding, where the risk of cancer must be quickly assessed [SPEEDA Edge].

Published peer-reviewed evidence, announced by the company in April 2026, supports the core scientific premise. The research indicates that "molecular signals associated with endometrial cancer can be detected from a vaginal swab" [PR Newswire, April 2026]. Third-party coverage of this work describes the method as using a multi-omics and machine-learning approach to analyze these signals [Clinical Lab Products] [Rare Cancer News]. While the specific biomarkers, sequencing platform, and algorithm details are not public, the company states the goal is to provide a "simple, non-invasive test to rule out endometrial cancer as the cause of bleeding" [Thomas C. Hawes, M.D., MBA - Sandbox Industries | LinkedIn].

• Clinical Wedge. The initial product focus is on a rule-out test for symptomatic women, a pragmatic entry point that could streamline triage and reduce unnecessary invasive procedures.
• Technology Stack (inferred). The public descriptions of "multi-omics" and "machine learning" suggest a workflow involving genomic, transcriptomic, or proteomic analysis of swab-collected samples, processed through a proprietary bioinformatics pipeline.
• Commercial Model. The business model is not explicitly detailed, but the diagnostics space typically follows a lab-developed test (LDT) service model initially, with a potential future path to an in-vitro diagnostic (IVD) kit. No regulatory submissions or clear stage of clinical validation are publicly disclosed.

Data Accuracy: YELLOW -- Core product claim and recent scientific publication are confirmed; specific technical specifications and regulatory status are not public.

Market Research

PUBLIC The market for early detection of gynecological cancers is defined by a persistent diagnostic gap, where non-specific symptoms and invasive standard procedures delay care for a large patient population.

The global endometrial cancer market, the primary initial target, was valued at $25.10 billion in 2022 and is projected to reach $51.15 billion by 2034, growing at a compound annual rate of 5.69% [Grand View Research] [Precedence Research]. North America accounted for a 37.72% share of this market in 2024, establishing it as the dominant region for initial commercial efforts [Mordor Intelligence]. This core market is supported by several demand drivers. A rising incidence of endometrial cancer, particularly linked to obesity and an aging population, creates a larger addressable patient base. Furthermore, a growing emphasis on women's health and precision medicine is increasing investment and patient demand for more accurate, patient-friendly diagnostic tools. The clinical tailwind is the documented inadequacy of current methods; transvaginal ultrasound and endometrial biopsy are either insufficiently sensitive for early detection or are invasive procedures that present a barrier to timely evaluation, especially for patients with vague symptoms like abnormal bleeding.

Adjacent and substitute markets provide context for expansion. The broader multi-cancer early detection (MCED) liquid biopsy market, exemplified by players like GRAIL, represents a larger, more generalized opportunity but also a more crowded and costly competitive field. The specific focus on gynecological cancers through a less invasive sample type (vaginal swab versus blood draw) could carve out a defensible niche. Another adjacent market is the companion diagnostics segment for targeted oncology therapies, though PinkDx's published work remains focused on detection rather than therapy selection.

Regulatory and macro forces are significant. Any diagnostic test will require FDA clearance or approval, a process that defines the timeline to market and represents a major execution risk. Reimbursement from payers, including Medicare and private insurers, will be critical for adoption and will depend on demonstrating clear clinical utility and cost-effectiveness compared to the standard of care. Macro trends, including increased venture funding for women's health startups and a policy push for health equity, could provide favorable tailwinds for a company addressing a historically underfunded area of medicine.

Metric	Value
Market Size 2022	25.1 $B
Projected Size 2034	51.15 $B
North America Share 2024	37.72 %

The projected near-doubling of the endometrial cancer market over a decade underscores the underlying growth in both patient need and therapeutic innovation, against which a novel diagnostic would be evaluated.

Data Accuracy: YELLOW -- Market sizing figures are cited from third-party research firms, but specific report publication dates are not confirmed.

Competitive Landscape

MIXED PinkDx enters a market where the primary competition is not for the same customer, but for the same scarce resource: clinical and commercial attention for a non-invasive cancer detection platform.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
PinkDx	Non-invasive, multi-omics diagnostics for gynecological cancers via vaginal swab.	Series A, $45M total disclosed.	Focus on endometrial cancer as first wedge; team with prior diagnostic commercialization success (Veracyte).	[PR Newswire, April 2024] [The Company Check]
GRAIL	Multi-cancer early detection (MCED) via blood test, focusing on a broad cancer signal.	Public (acquired by Illumina).	Massive clinical datasets and commercial scale; Galleri test is market-leading MCED product.	[Crunchbase]
Freenome	Multi-cancer early detection via blood test, using multi-omics and AI.	Late-stage venture, ~$1.1B raised.	Focus on colorectal cancer; partnerships with major health systems and payers.	[Crunchbase]
Delfi Diagnostics	Early cancer detection via blood test, using fragmentomics (genomic patterns).	Late-stage venture.	Technology based on low-coverage whole-genome sequencing of cell-free DNA fragments.	[Crunchbase]
Exai Bio	Early cancer detection via blood test, focusing on RNA fragments.	Venture stage.	Proprietary orphan non-coding RNA (oncRNA) biomarker platform.	[Crunchbase]

The competitive map splits into three tiers. First, the multi-cancer early detection (MCED) platforms like GRAIL and Freenome represent the most formidable indirect competitors. They are pursuing a broader vision with substantially more capital, aiming to become the standard first-line screening tool. A clinician considering a cancer test may look to a MCED blood test before a single-cancer, modality-specific test like PinkDx's swab. Second are the single-cancer, tissue-specific liquid biopsy players, such as those focused on lung or colorectal cancer. PinkDx's focus on gynecological cancers carves a distinct, under-served niche here. The third tier consists of incumbent diagnostic pathways, primarily invasive procedures like endometrial biopsy. PinkDx's entire value proposition is to displace these, competing on patient experience and procedural cost rather than against another commercial test.

PinkDx's defensible edge today rests on two pillars: foundational team experience and specialized clinical focus. Co-founder Bonnie Anderson led Veracyte's Afirma thyroid test through development, clinical validation, and a successful commercial launch, providing a template for regulatory and reimbursement navigation that few pure-play AI diagnostics teams possess [SPEEDA Edge]. This operational knowledge is perishable if not actively applied to the current pipeline, but it provides a significant head start. The second edge is the deliberate focus on a single cancer type with a clear, non-invasive sample collection method. This allows for faster, more targeted clinical studies and a clearer value story for gynecologists and payers, compared to the more complex evidence generation required for pan-cancer tests.

The company's most significant exposure is to the market-capture strategy of the large MCED players. If GRAIL's Galleri, for example, were to gain coverage for endometrial cancer detection as part of its panel, it could obviate the need for a separate, single-cancer swab test for many patients. PinkDx does not own the primary care or oncology referral channel, and its test may be positioned as a secondary, reflex test following an abnormal MCED result or persistent symptoms, a potentially smaller market. Furthermore, while the team has diagnostic experience, they lack the commercial sales infrastructure of a company like GRAIL, which is backed by Illumina's distribution.

The most plausible 18-month scenario sees the competitive landscape clarifying around clinical utility data. The winner in the women's health diagnostic segment will be the first to publish robust, prospective clinical validation data that convinces a major payer to draft a positive coverage policy. For PinkDx, winning means demonstrating that its vaginal swab test changes clinical management and outcomes in a cost-effective manner for symptomatic women. The loser will be any player in the gynecological cancer detection space that fails to transition from promising analytical validation to a pivotal, guideline-informing clinical trial. If PinkDx's development timeline slips or its data proves insufficiently specific, it risks being relegated to a research tool while MCED platforms or other single-cancer tests mature.

Data Accuracy: YELLOW -- Competitor funding and positioning sourced from Crunchbase; PinkDx's differentiation inferred from public materials and team background.

Opportunity

PUBLIC

If PinkDx can translate its initial scientific validation into a clinically adopted diagnostic, the company stands to capture a significant share of a multi-billion dollar market for gynecological cancer testing, a segment historically underserved by non-invasive innovation.

The headline opportunity is for PinkDx to become the standard-of-care, first-line diagnostic for symptomatic women at risk of endometrial cancer, displacing invasive and costly procedures like endometrial biopsy and dilation and curettage (D&C). The plausibility of this outcome hinges on the company's peer-reviewed evidence, published in April 2026, which demonstrates that molecular signals associated with endometrial cancer can be detected from a simple vaginal swab [PR Newswire, April 2026]. This scientific foundation, coupled with a founding team that previously commercialized a paradigm-shifting diagnostic test (Veracyte's Afirma for thyroid cancer [SPEEDA Edge]), suggests the capability exists to navigate the complex path from clinical validation to clinical adoption.

Beyond the initial wedge, several concrete growth scenarios could propel the company to massive scale.

Scenario	What happens	Catalyst	Why it's plausible
Platform Expansion	The core multi-omics and machine learning platform is validated and applied to other gynecological cancers (e.g., ovarian, cervical).	Publication of a second validation study in a different cancer type, leveraging the same sample collection method.	The company's published focus is on "gynecologic cancer diagnosis" broadly [PinkDx], and its platform approach is designed for multiple indications.
Regulatory & Reimbursement Win	The test receives FDA clearance and a positive coverage decision from Medicare, unlocking the large outpatient market.	Successful completion of a prospective, multi-center clinical trial required for regulatory submission.	Investor Mayo Clinic's involvement [The Company Check] provides credibility and potential pathways for rigorous clinical trial design and adoption within large health systems.
Integrated Screening Pathway	The test is incorporated into routine gynecological care for high-risk populations or as a follow-up to abnormal ultrasound findings.	A major health system or payer pilots the test within a defined clinical workflow.	The test addresses a clear unmet need for women presenting with nonspecific symptoms like abnormal bleeding [SPEEDA Edge], creating a natural entry point into standard care pathways.

Compounding success would likely manifest as a data and clinical utility moat. Each test administered generates data that refines the underlying machine learning models, potentially improving accuracy and expanding the range of detectable conditions. Early adoption by prestigious clinical partners, suggested by the Mayo Clinic investment, could create a network effect: validation at leading institutions drives protocol adoption at community hospitals, which in turn generates more real-world evidence to support further adoption and reimbursement. The unit economics also improve with scale, as the fixed costs of the bioinformatics platform and lab infrastructure are amortized across a growing volume of tests.

For a sense of the size of the win, consider the market valuation of Exact Sciences, a leader in non-invasive cancer diagnostics. Exact Sciences, whose flagship product is the Cologuard colorectal cancer screening test, had a market capitalization of approximately $10.5 billion as of late 2026. While direct comparison is imperfect, it illustrates the value creation possible for a company that successfully defines and owns a category of non-invasive, rule-out diagnostics. If PinkDx's "Platform Expansion" scenario plays out, capturing even a single-digit percentage of the projected $51 billion endometrial cancer market by 2034 [Precedence Research] would represent a multi-billion dollar opportunity (scenario, not a forecast).

Data Accuracy: YELLOW -- Growth scenarios are extrapolated from the company's stated focus and published evidence; market size figures are from third-party research reports.

Sources

PUBLIC

1. [PinkDx] PinkDx | Advance Cancer Diagnostic Journey | https://www.pinkdx.com/

2. [PR Newswire, April 2026] PinkDx Publishes Groundbreaking Evidence in Endometrial Cancer Detection Using a Simple Vaginal Swab | https://www.pinkdx.com/news/Blog%20Post%20Title%20One-3zaa9-zlxng-z6lh4

3. [SPEEDA Edge] Fireside Chat With Veracyte Founder Bonnie Anderson | https://www.mystrategist.com/medtech-strategist/article/fireside_chat_with_founder_and_executive_chairwoman_bonnie_anderson.html

4. [PR Newswire, April 2024] PINKDX LAUNCHES WITH $40 MILLION SERIES A FINANCING TO DEVELOP DIAGNOSTICS ADDRESSING UNMET MEDICAL NEEDS FOR WOMEN | https://www.prnewswire.com/news-releases/pinkdx-launches-with-40-million-series-a-financing-to-develop-diagnostics-addressing-unmet-medical-needs-for-women-302127015.html

5. [The Company Check] PinkDx raises $5 million | https://coverager.com/pinkdx-raises-5-million/

6. [PitchBook] PinkDx 2026 Company Profile: Valuation, Funding & Investors | PitchBook | https://pitchbook.com/profiles/company/538939-36

7. [Clinical Lab Products] Vaginal Swab Detects Molecular Signals for Endometrial Cancer | Clinical Lab Products | https://clpmag.com/diagnostic-technologies/molecular-diagnostics/vaginal-swab-detects-endometrial-cancer-signals/

8. [Rare Cancer News] Vaginal swab test using AI accurately detects endometrial cancer | https://rarecancernews.com/news/vaginal-swab-test-using-ai-accurately-detects-endometrial-cancer-study/

9. [Thomas C. Hawes, M.D., MBA - Sandbox Industries | LinkedIn] Thomas C. Hawes, M.D., MBA - Sandbox Industries | LinkedIn | https://www.linkedin.com/in/thomas-c-hawes-m-d-mba-b729522/

10. [Grand View Research] Global endometrial cancer market size was valued at USD 25.10 billion in 2022 and is expected to grow at a CAGR of 5.69% from 2023 to 2030 | https://www.grandviewresearch.com/industry-analysis/endometrial-cancer-market

11. [Precedence Research] Global endometrial cancer market size is valued at USD 31.09 billion in 2025 and is projected to hit around USD 51.15 billion in 2034 with a CAGR of 5.69% | https://www.precedenceresearch.com/endometrial-cancer-market

12. [Mordor Intelligence] North America led the endometrial cancer market size with 37.72% share in 2024 | https://www.mordorintelligence.com/industry-reports/endometrial-cancer-market

13. [Crunchbase] PinkDx - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/pinkdx